The iRhythm Zio Patch was cleared by the FDA for use only by physician prescription using the 510(k) pathway as the product was deemed 'substantially equivalent' to predicate devices. We presented ...

The Zio AI continuous monitoring system combines a wearable electrocardiogram (ECG) patch, named the Zio AT patch, with the ZEUS system, iRhythm’s AI-powered software for ECG analysis.

The stock of iRhythm went from $30 to $285 over a similar stretch, as its Zio ECG-patch won most of the medical market for the long-term monitoring that determines if heart flutters actually are AFib.

Zio XT has been recommended by NICE as an option ... At the end of the monitoring period, users remove the patch and send it via freepost for analysis using artificial intelligence algorithms ...

Why do digital health startups keep failing? The "move fast and break things" approach that works in tech doesn't translate well to healthcare. Instead, digital health startups should try need ...

Drawing on data from more than 1.1 million patients who used iRhythm’s Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour ...

There is no public information as to why the Heart Check device was approved by the US FDA for direct sale to individuals, yet the AliveCor and Zio Patch products require prescription by a US ...